Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2β) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials

MLA

Grijse, J., et al. “Predictive Power of Screening for Antibodies against Insulinoma-Associated Protein 2 Beta (IA-2β) and Zinc Transporter-8 to Select First-Degree Relatives of Type 1 Diabetic Patients with Risk of Rapid Progression to Clinical Onset of the Disease: Implications for Prevention Trials.” Diabetologia, vol. 53, no. 3, Mar. 2010, pp. 517–24. EBSCOhost, https://doi.org/10.1007/s00125-009-1618-y.

APA

Grijse, J., Asanghanwa, M., Nouthe, B., Albrecher, N., Goubert, P., Vermeulen, I., Meeren, S., Decochez, K., Weets, I., Keymeulen, B., Lampasona, V., Wenzlau, J., Hutton, J., Pipeleers, D., & Gorus, F. (2010). Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2β) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia, 53(3), 517–524. https://doi.org/10.1007/s00125-009-1618-y

Chicago

Grijse, J., M. Asanghanwa, B. Nouthe, N. Albrecher, P. Goubert, I. Vermeulen, S. Meeren, et al. 2010. “Predictive Power of Screening for Antibodies against Insulinoma-Associated Protein 2 Beta (IA-2β) and Zinc Transporter-8 to Select First-Degree Relatives of Type 1 Diabetic Patients with Risk of Rapid Progression to Clinical Onset of the Disease: Implications for Prevention Trials.” Diabetologia 53 (3): 517–24. doi:10.1007/s00125-009-1618-y.